retatrutide side effects phase 2 trial VisualAbstract: reduces body weight by 17.5% in patients with obesity Retatrutide Side Effects Research |

FDA has explained: compounded drugs pose a higher risk to patients than FDA-approved drugs, and that the unnecessary use of compounded drugs exposes patients to potentially serious health risks. Lilly has discovered compounded drugs advertised as tirzepatide with safety, sterility, and efficacy problems

It has been proven to achieve a substantial average reduction in body weight in clinical trials

If 10% of the target population (an estimated 360,000 people) uses Wegovy for a full year, that would amount to additional net Medicare Part D spending of $2.8 billion for one year for this one drug alone

The LEADER trial demonstrated a significant reduction in the rate of cardiovascular death, nonfatal MI, or nonfatal stroke in patients with type II diabetes treated with liraglutide